• Publications
  • Influence
Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
Abstract The chemotherapy currently available for leishmaniasis is far from satisfactory. Resistance to the pentavalent antimonials, which have been the recommended drugs for the treatment of bothExpand
  • 767
  • 41
  • PDF
In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs
ABSTRACT The interaction of miltefosine with amphotericin B, sodium stibogluconate, paromomycin, and sitamaquine was assessed in vitro and additionally for the first three combinations in vivo. InExpand
  • 171
  • 15
  • PDF
Chemotherapy of leishmaniasis.
Leishmaniasis, in its variety of visceral (VL), cutaneous (CL) and mucocutaneous (MCL) forms, directly affects about 2 million people per annum, with approximately 350 million individuals at riskExpand
  • 197
  • 12
Leishmaniasis chemotherapy--challenges and opportunities.
Although there have been significant advances in the treatment of visceral leishmaniasis (VL), there remain challenges to ensure that treatments effective in India are also effective in other regionsExpand
  • 320
  • 10
  • PDF
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.
Miltefosine (hexadecylphosphocholine, MIL), registered as Impavido((R)), has become the first oral drug for the treatment of visceral and cutaneous leishmanasis. MIL is a simple molecule, veryExpand
  • 177
  • 10
  • PDF
A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
  • V. Yardley, S. Croft
  • Biology, Medicine
  • International journal of antimicrobial agents
  • 1 February 2000
The polyene antibiotic, amphotericin B, the gold standard for systemic fungal infections is also a recommended second line treatment for visceral, cutaneous and mucocutaneous leishmaniasis. AcuteExpand
  • 149
  • 9
Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).
Leishmania donovani promastigote lines resistant to hexadecylphosphocholine (HePC, miltefosine) at 2.5, 5.0, 10.0, 20.0 and 40.0 microM were developed in vitro by continuous step-wise drug pressure.Expand
  • 163
  • 8
Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.
The sensitivities of both promastigote and amastigote stages of six species of Leishmania, L. donovani, L. major, L. tropica, L. aethiopica, L. mexicana and L. panamensis, were determined in vitro toExpand
  • 196
  • 6
In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent.
OBJECTIVES To evaluate the in vitro activity of anti-leishmanial drugs against intracellular Leishmania donovani amastigotes in different types of macrophages. METHODS Mouse peritoneal macrophagesExpand
  • 109
  • 6
  • PDF
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Miltefosine (hexadecylphosphocholine) is the first oral antileishmanial drug. In this study, we addressed the question whether miltefosine-resistant Leishmania donovani promastigotes transform toExpand
  • 125
  • 6